An engineered recombinant protein containing three structural domains in SARS-CoV-2 S2 protein has potential to act as a pan-human coronavirus entry inhibitor or vaccine antigen

An engineered recombinant protein containing three structural domains in SARS-CoV-2 S2 protein has potential to act as a pan-human coronavirus entry inhibitor or vaccine antigen

The threat to global health caused by three highly pathogenic human coronaviruses (HCoV), SARS-CoV-2, MERS-CoV and SARS-CoV, calls for the development of pan-HCoV therapeutics and vaccines. This study reports the design and engineering of a recombinant protein designated HR1LS. It contains three lin...

Full description

Saved in:
Bibliographic Details
Main Authors: Xinling Wang, Lujia Sun, Zezhong Liu, Lixiao Xing, Yun Zhu, Wei Xu, Shuai Xia, Lu Lu, Shibo Jiang
Format: Article
Language:English
Published: Taylor & Francis Group 2023-12-01
Series:Emerging Microbes and Infections
Subjects:
Coronavirus
pan-human coronavirus
stem helix
entry inhibitor
vaccine
Online Access:https://www.tandfonline.com/doi/10.1080/22221751.2023.2244084
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items

Similar Items